Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Exposure of AZD1390 in Healthy Volunteers
NCT03215381Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd1390 in glioblastoma (GBM), sponsored by AstraZeneca. Primary endpoint: Brain distribution of AZD1390 at 2 hours. Started Oct 2017; status: completed.
02
Drugs
azd1390
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03215381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215381.